GlassScriptPhysician profile
Amanda M Harrell
NPI 1891138848
$3,358.23
in general payments reported to CMS, 2019-2025
41 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $364 · 2021: $546 · 2022: $466 · 2023: $499 · 2024: $550 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.03 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $336.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $324.87 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.98 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $244.06 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $166.00 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $160.56 | 2019-2025 | |
| Dexcom, INC. | $157.65 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $102.69 | 2021-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.28 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $88.59 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.38 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $62.19 | 2020-2024 | |
| Amarin Pharma, INC. | $59.12 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $56.15 | 2023-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.